Market news

Zimmer Biomet currently trades at $91.50 per share and has shown little upside over the past six months, posting a middling return of 4.4%. The stock also fell short of the S&P 500’s 16.9% gain during that period.

Zimmer Biomet Holdings: recent performance and context Zimmer Biomet Holdings (ZBH) has drawn investor attention after a stretch of weaker share performance, with the stock down 1.3% over the past day and 10.5% over the past month. At a share price of US$89.69, Zimmer Biomet Holdings has seen momentum fade recently, with the 30-day share price return down 10.5% and the 1-year total shareholder return declining 6.5%. This points to cooler sentiment following earlier periods of...

A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

As Zimmer Biomet has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Zimmer Biomet Holdings (ZBH) promoted Gary Campbell to President, Americas, and Brian Hatcher to Pre

Zimmer Biomet Holdings is seeing constant currency sales growth driven by transformation factors, R&D, and M&A efforts. Read more on ZBH stock here.

ZBH's growth outlook is backed by healthy procedure demand and Z1, HAMMR and OrthoGrid adoption, though debt and competition remain concerns.

Zimmer Biomet Holdings has seen its share price decline about 27.9% over the past five years, yet the stock still screens as attractively priced on several valuation checks. This raises questions for investors trying to reconcile weak long term returns with a more positive current valuation read. Over the past five years the stock has declined about 27.9%, which signals that long term holders have not yet been rewarded despite the recent rebound. The ongoing shift to a fully dedicated sales...

Zimmer Biomet has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Zimmer Biomet’s second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such as the Z1 hip stem and OrthoGrid navigation, contributed to above-average growth in the U.S. In addition, increased demand for the company’s technology and data solutions, including capital equipment sales, played a key role. Management attributed the quarter’s perform

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $104.90, a

Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $103.80, a

The restructuring, intended to give Zimmer Biomet a fully dedicated sales force, is expected to be complete by the end of 2027.

Zimmer Biomet Holdings Inc (ZBH) raises full-year outlook on robust US hip and technology growth, while navigating ongoing commercial transformation and international headwinds.

Moby summary of Zimmer Biomet Holdings, Inc.'s Q2 2026 earnings call

Zimmer Biomet Holdings (ZBH) has an average rating of overweight and mean price target of $96.95, ac

Zimmer released its Q2 financials ahead of market open, prompting its shares on the New York Stock Exchange to rise by over 5% at market open on 5 August.